EF Hutton Initiates Coverage On Humacyte With Buy Rating, Announces Price Target of $25
EF Hutton Initiates Humacyte(HUMA.US) With Buy Rating, Announces Target Price $25
Humacyte Price Target Maintained With a $15.00/Share by Benchmark
Humacyte Analyst Ratings
Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $15
Benchmark Co. Remains a Buy on Humacyte (HUMA)
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10
Humacyte Analyst Ratings
Benchmark Reiterates Buy on Humacyte, Maintains $15 Price Target
Benchmark Co. Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $15
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $10
Humacyte Analyst Ratings
TD Cowen Sticks to Its Buy Rating for Humacyte (HUMA)
Analysts Conflicted on These Healthcare Names: Edgewise Therapeutics (EWTX), Humacyte (HUMA) and Apellis Pharmaceuticals (APLS)
Humacyte (HUMA) Gets a Hold From Piper Sandler
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Raises Target Price to $10
Buy Rating Affirmed for Humacyte Amid Superior ATEV Clinical Results and Market Opportunity
Humacyte Analyst Ratings
Humacyte Analyst Ratings
Humacyte (HUMA) Gets a Buy From Benchmark Co.